Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer

摘要: Neo-angiogenesis is a critical process for tumor growth and invasion has become promising target in cancer therapy. This manuscript reviews three currently relevant anti-angiogenic agents targeting the vascular endothelial factor system: bevacizumab, ramucirumab sorafenib. The efficacy of drugs adjuvant therapy or as neo-adjuvant treatment been estimated clinical trials advanced breast cancer. To date, overall observed improvements are unconvincing, further research required to demonstrate treatments. outcomes have highly variable terms response. New methods needed identify patients who will benefit from this regimen. development biomarkers molecular profiling areas that may strengthen ability focus towards suitable patients, thereby increase cost-effectiveness, be inadequate.